Healthcare Finance News November 26, 2024
Susan Morse

The proposed rule would need to become final under the Trump Administration.

On Tuesday, the Centers for Medicare and Medicaid Services announced a proposed rule for coverage of obesity drugs in Medicare and Medicaid, starting in 2026.

After notice and comment rulemaking, the rule would need to be finalized under the Trump Administration. Comments must be submitted no later than January 27, 2025.

An estimated 3.4 million people would be newly able to obtain coverage for obesity drugs under Medicare Part D, CMS estimated. The cost to the federal government over 10 years would be $25 billion.

CMS expects no short-term premium impact, said Dr. Meena Seshamani, deputy administrator and director, CMS, during a call with reporters on Tuesday morning.

...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicaid, Medicare, Pharma / Biotech
After slow start, ACA enrollment takes off
CMS says record 16.6 million have signed up for Jan. 1 Marketplace coverage
How has U.S. Spending on Health Care Changed Over Time?
CMS Launches New Program for Mental Health, OUD Treatment
CMS ending VBID model due to high costs

Share This Article